Clinical Trials (Phase III)
Filter News
Found 14,302 articles
-
Denmark-based LEO Pharma and California rare disease drugmaker PellePharm entered into a strategic collaboration worth $760 million to address unmet needs in multiple orphan skin diseases, such as Gorlin Syndrome and High-Frequency Basal Cell Carcinomas (BCCs), two rare forms of skin cancer.
-
Stallergenes Greer Announces That the Phase III Trial for Its Sublingual Allergy Immunotherapy Tablet STAGR320 to Treat House Dust Mite-Induced Allergic Rhinitis Achieved Its Primary Endpoint
11/20/2018
The study achieved its primary efficacy endpoint (p<0.0001)
-
An ovarian cancer treatment co-developed by Germany’s Merck KGaA and Pfizer failed to meet endpoints for overall survival and progression-free survival in a Phase III trial.
-
It is estimated that 2.5 percent of all children in the U.S. might have a peanut allergy. Since 2010, according to the America College of Allergy, Asthma and Immunology, incidence of peanut allergies in children had risen 21 percent in the U.S.
-
GlycoMimetics Enrolls First Patient in Global Phase 3 Clinical Trial of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia
11/19/2018
Pivotal Trial to Evaluate Efficacy and Safety of Uproleselan in Patients with Advanced Acute Myeloid Leukemia (AML); Trial to Enroll 380 Patients at US and International Sites
-
Blue Earth Diagnostics Announces Results of Investigational Phase 3 Blinded Image Evaluation Study of 18F-Fluciclovine PET Imaging in Glioma
11/19/2018
Presented at 23rd Annual Scientific Meeting of the Society for Neuro-Oncology
-
Updated Interim Data from Phase 3 Trial of DCVax®-L for Glioblastoma Presented at Society for Neuro-Oncology Conference
11/19/2018
Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that updated blinded interim data from the Phase 3 trial of DCVax®-L for Glioblastoma brain cancer were presented by Dr. Linda Liau at the 23rd Annual Meeting of the Society for Neuro-Oncology.
-
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
11/19/2018
Compared with PLD did not meet the prespecified primary endpoints of overall survival or progression-free survival in patients with platinum-resistant or -refractory ovarian cancer.
-
Landmark PALISADE Trial of AR101 Published in New England Journal of Medicine
11/18/2018
Treatment with AR101 significantly increased the amount of peanut protein tolerated and reduced the number and severity of reactions to peanut protein
-
AstraZeneca is attempting to find encouraging news in the failure of its MYSTIC clinical trial, but it doesn’t look good.
-
Sollis Therapeutics Announces the First Patient Enrolled in a Phase 3 Clinical Trial of Clonidine Micropellet for Sciatica
11/16/2018
Sollis Therapeutics, Inc., an Ohio-based interventional pain therapeutics company, announced that the first patient was enrolled in the RePRIEVE-CM trial, a Phase 3 clinical trial evaluating the efficacy and safety of the extended release non-opioid, non-steroid clonidine micropellet for the treatment of sciatica pain.
-
One Busy Week for AbbVie: Hepatitis C, Fibroids, Alzheimer’s & Parkinson’s, and Generic Criticism
11/15/2018
AbbVie presented additional data from two Phase III clinical trials in women with uterine fibroids. In a big news week for the company, what else is AbbVie up to? -
Deciphera Pharmaceuticals Completes Enrollment in the INVICTUS Pivotal Phase 3 Clinical Study of DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors
11/15/2018
- Company Expects to Report Top-line Data in Mid-2019 and is Building the Commercial Capabilities to Support the Planned Launch of DCC-2618 in the United States -
-
Biohaven Enrolls First Patient In Phase 3 Preventive Treatment Of Migraine Trial With Its Oral CGRP Receptor Antagonist Rimegepant
11/15/2018
Rimegepant is the only oral CGRP receptor antagonist currently in development for both the acute and preventive treatment of migraine
-
Arena Pharmaceuticals and United Therapeutics Announce Global License Agreement for Ralinepag
11/15/2018
Arena will receive $800M upfront, and is eligible to receive low double-digit tiered royalties, plus up to $400M in milestone payments
-
Chicago-based AbbVie just announced new data for its Mavyret (glecaprevir/pibrentasvir), a pan-genotypic treatment for chronic HCV in treatment-naive patients with compensated cirrhosis.
-
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Compared to Chemotherapy in Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)
11/14/2018
With Pivotal KEYNOTE-181 Trial Meeting Primary Endpoint of OS, KEYTRUDA Becomes the First Anti-PD-1 Therapy to Demonstrate a Survival Benefit for These Patients
-
AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress
11/14/2018
Elagolix, in combination with add-back therapy, achieved statistically significant reduction in heavy menstrual bleeding associated with uterine fibroids compared to placebo
-
Circulating Tumor Cells Detected From Angiosarcoma Cancer Patients With Use Of ApoStream® Technology In A First-of-its-kind Study
11/14/2018
PROMISING RESULTS DERIVED FROM THE PIVOTAL PHASE 3 TAPPAS TRIAL OF TRC105 AND VATRIENT® IN PATIENTS WITH ADVANCED ANGIOSARCOMA.
-
First patient Enrolled in Pivotal Clinical Phase 3 Study NEFIGARD with Lead Candidate Nefecon
11/13/2018
Calliditas Therapeutics AB today announced that the first patient has been enrolled in the company's pivotal clinical phase 3 study NEFIGARD in patients with IgA nephropathy (IgAN).